TLSI (TLSI) Securities Fraud Investigation - Levi & Korsinsky

TriSalus Life Sciences Inc. reaffirmed $60-$62 million revenue guidance on March 5, 2026. Months later, the company cut that outlook to $54-$57 million after missing Q1 estimates.